Table 1. Comparison of FDA-approved indications for hepatitis C antiviral agents^1,16–18.

	Sofosbuvir	Boceprevir	Simeprevir	Telaprevir
Brand name	Sovaldi	Victrelis	Olysio	Incivek
Manufacturer	Gilead Sciences	Merck	Janssen	Vertex Pharmaceuticals
Approval date	December 6, 2013	May 13, 2011	November 22, 2013	May 23, 2011
Indication	Treatment of chronic hepatitis C as a component of a combination antiviral treatment regimen; efficacy established in subjects with HCV genotype 1, 2, 3, or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 coinfection	Chronic HCV genotype 1 infection in adult patients with compensated liver disease, including cirrhosis, who are treatment naive or who have failed previous therapy with interferon and ribavirin, including prior null responders, partial responders, and relapsers	Chronic HCV genotype 1 infection in adult patients with compensated liver disease, including cirrhosisa	Chronic HCV genotype 1 infection in adult patients with compensated liver disease, including cirrhosis, who are treatment naive or who have failed previous therapy with interferon-based treatment, including prior null responders, partial responders, and relapsers

Note: HCV = hepatitis C virus; HIV = human immunodeficiency virus.

^aSimeprevir has been studied in treatment-naive patients and patients who have failed previous therapy with peginterferon and ribavirin, and the US Food and Drug Administration (FDA)-approved labeling contains dosing recommendations for patients who are treatment naive or who have failed previous therapy with interferon and ribavirin, including prior null responders, partial responders, and relapsers, although these populations are not specified in the indication.